MetaVia Inc. Common Stock
$1.73
$0.14 (+8.81%)
$1.55Day Range$1.73
Key Statistics
Market Cap
$11.40M
Shares Outstanding
6.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 4, 2016
Round Lot
100
Locale
US
Trading Data
Day Open
$1.55
Day High
$1.73
Day Low
$1.55
Volume
108.7K
VWAP
$1.66
Prev Close
$1.59
Transactions
--
Acc. Volume
--
About MetaVia Inc. Common Stock
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
PHARMACEUTICAL PREPARATIONSSIC 28348 employees545 CONCORD AVENUE, CAMBRIDGE, MA, 02138(857) 702-9600IPO Aug 4, 2016US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001638287
- Composite FIGI
- BBG009YPPXR8
- Share Class FIGI
- BBG009YPPXS7
- Ticker Root
- MTVA
- SIC Code
- 2834
About MetaVia Inc. Common Stock (MTVA) Stock
MetaVia Inc. Common Stock (MTVA) closed the 2026-09-18 session at $1.73, up 8.81% versus the previous close (+0.14). The stock opened at $1.55 and traded between $1.55 and $1.73 during that session. Session trading volume was 109K shares. The volume-weighted average price (VWAP) is $1.66.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
MetaVia Inc. Common Stock has a market capitalization of $11.4 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MTVA is listed on the XNAS exchange. The company employs approximately 8 people. MetaVia Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2016-08-04.
On this page you can find market MTVA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.